Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-06-12
2007-06-12
Schnizer, Richard (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S325000
Reexamination Certificate
active
10446519
ABSTRACT:
The present invention provides novel antisense ribozymes useful for inhibiting the activity of neutral sphingomyelinase. Also provided are methods for reducing the activity of neutral sphingomyelinase, as well as methods for reducing apoptosis and atherosclerosis using the ribozymes of the invention.
REFERENCES:
patent: 5616490 (1997-04-01), Sullivan et al.
patent: 5750390 (1998-05-01), Thompson et al.
Tonnetti et al. Journal of Experimental Medicine 1999 vol. 189, pp. 1581-1589.
A. Alessenko, et al., “Neutral Sphingomyelinase: Localization in Rat Liver Nuclei and Involvement in Regeneration/Proliferation,” Molecular and Cellular Biochemistry, vol. 143, 1995, pp. 169-174.
H. Birbes, et al., “Selective Hydrolysis of a Mitochondrial Pool of Sphingomyelin Induces Apoptosis,” The FASEB Journal, vol. 14, Dec. 2001, pp. 2669-2679.
S. Chatterjee, et al., “Molecular Cloning, Characterization, and Expression of a Novel Human Neutral Sphingomyelinase,” The Journal of Biological Chemistry, vol. 274, No. 52, Dec. 24, 1999, pp. 37407-37412.
S. Chatterjee, “Neutral Sphingomyelinase,” Advances in Lipid Research, vol. 26, 1993, pp. 25-48.
S. Chatterjee, “Neutral Sphingomyelinase Action Stimulates Signal Transduction of Tumor Necrosis Factor-α in the Synthesis of Cholesteryl Esters in Human Fibroblasts,” The Journal of Biological Chemistry, vol. 269, No. 2, Jan. 14, 1994, pp. 879-882.
S. Chatterjee, et al., “Neutral Sphingomyelinase from Human Urine: Purification and Preparation of Monospecific Antibodies,” The Journal of Biological Chemistry, vol. 264, No. 21, Jul. 25, 1989, pp. 12554-12561.
S. Chatterjee, “Neutral Sphingomyelinase Increases the Building, Internalization, and Degradation of Low Density Lipoproteins and Synthesis of Cholesteryl Ester in Cultured Human Fibroblasts,” The Journal of Biological Chemistry, vol. 268, No. 5, Feb. 15, 1993, pp. 3401-3406.
S. Chatterjee, “Neutral Sphingomyelinase: Past, Present and Future,” Chemistry and Physics of Lipids, vol. 102, 1999, pp. 79-96.
S. Chatterjee, et al., “Oxidized Low Density Lipoprotein Stimulates Aortic Smooth Muscle Cell Proliferation,” Glycobiology, vol. 6, No. 3, 1996, pp. 303-311.
S. Chatterjee, et al., “Purification of Neutral Sphingomyelinase from Human Urine,” Methods in Enzymology, vol. 197, 1991, pp. 540-547.
C. Guerrier-Takada, et al., “The RNA Moiety of Ribonuclease P is the Catalytic Subunit of the Enzyme,” Cell, vol. 35, Dec. 1983 (Part 2), pp. 849-857.
A. Hampel, et al., “RNA Catalytic Properties of the Minimum (−)sTRSV Sequence,” Biochemistry, vol. 28, 1989, pp. 4929-4933.
A. Hampel, et al., “Hairpin' Catalytic RNA model: Evidence for Helices and Sequence Requirement for Substrate RNA,” Nucleic Acids Research, vol. 18, No. 2, 1990, pp. 299-304.
Y. Hannun, “The Sphingomyelin Cycle and the Second Messenger Function of Ceramids,” The Journal of Biological Chemistry, vol. 269, No. 5, Feb. 4, 1994, pp. 3125-3128.
B. Liu, et al., “Inhibition of the Neutral Magnesium-Dependent Sphingomyelinase by Glutathione,” The Journal of Biological Chemistry, vol. 272, No. 26, Jun. 27, 1997, pp. 16281-16287.
S. Martin, et al., “Glycosphingolipid-Induced Cell Signaling: Apoptosis,” Methods in Enzymology, vol. 363, 2003, pp. 284-299.
R. Montgomery, et al., “Inhibition of Fibrillin 1 Expression Using U1 snRNA as a Vehicle for the Presentation of Antisense Targeting Sequence,” Human Molecular Genetics, vol. 6, No. 4, 1997, pp. 519-525.
F. Paris, et al., “Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice,” Science Magazine, vol. 293, Jul. 13, 2001, pp. 293-297.
L. Peña, et al., “Stress-Induced Apoptosis and the Sphingomyelin Pathway,” Biochemical Pharmacology, vol. 53, 1997, pp. 615-621.
P. Peraldi, et al., “Tumor Necrosis Factor (TNF)-α Inhibits Insulin Signaling through Stimulation of the p55 TNF Receptor and Activation of Sphingomyelinase,” The Journal of Biological Chemistry, vol. 271, No. 22, May 31, 1996, pp. 13081-13022.
A. Perrotta, et al., “Cleavage of Ogligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence,” Biochemistry, vol. 31, No. 1, 1992, pp. 16-21.
J. Rossi, et al., “Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems,” Aids Research and Human retroviruses, vol. 8, No. 2, 1992, pp. 183-189.
P. Signorelli, et al., “Analysis and Quantitation of Ceramide,” Methods in Enzymology, vol. 345, 2002, pp. 275-294.
D. Sillence, “Apoptosis and Signalling I Acid Sphingomyelinase Deficient Cells,” BMC Cell Biology, vol. 2, No. 24, Nov. 12, 2001.
W. Stoffel, “Functional Analysis of Acid and Neutral Sphingomyelinases In Vitro and In Vivo, Chemistry and Physics of Lipids,” vol. 102, 1999, pp. 107-121.
S. Tomiuk, et al., “Cloned Mammalian Neutral Sphingomyelinase: Functions in Sphingolipid Signaling?,” Proceedings of the National Academy of Sciences of the USA, vol. 95, No. 7, Mar. 1998, pp. 3638-3643.
Chatterjee Subroto
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Schnizer Richard
Sparks Jonathan M.
LandOfFree
Neutral sphingomyelinase antisense ribozyme and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutral sphingomyelinase antisense ribozyme and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutral sphingomyelinase antisense ribozyme and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3843382